TKNO ALPHA TEKNOVA INC

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023

HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.

Teknova will host a webcast and conference call on Thursday, August 10, 2023, beginning at 5:30 p.m. Eastern Time. Participants can access the live webcast on the section of the Teknova website and at this link: . To receive a PIN number for dial in, participants can register for the webcast via this link: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova   

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. The Company’s fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps their customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by its team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies. 



Investor Contacts 
Matt Lowell 
Chief Financial Officer 
 
  

Sara Michelmore 
MacDougall Advisors 
  
  

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
   
  
EN
26/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Teknova Reports Fourth Quarter and Full Year 2025 Financial Results Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced...

 PRESS RELEASE

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results ...

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday...

 PRESS RELEASE

Teknova Reports Third Quarter 2025 Financial Results

Teknova Reports Third Quarter 2025 Financial Results Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30...

 PRESS RELEASE

Teknova to Report Third Quarter 2025 Financial Results on November 6, ...

Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, November 6, 2025, beginning a...

 PRESS RELEASE

Teknova Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch